[Long-term results of small cell lung cancer treated by surgery combined with postoperative chemotherapy: a report of 65 patients]

Zhonghua Zhong Liu Za Zhi. 1997 Mar;19(2):137-9.
[Article in Chinese]

Abstract

Objective: To analyse the long term results of small cell lung cancer (SCLC) treated by surgery combined with postoperative chemotherapy.

Methods: From 1983 to 1994, 65 patients with SCLC were treated by surgery combined with postoperative chemotherapy, and 22 of them received prophylactic cranial irradiation.

Results: In 64 evaluable patients, the overall 1-, 3- and 5-year survival rates were 87.5%, 53.2% and 36.3%. Patients treated by radical operation plus chemotherapy gave 1-, 3- and 5-year survival rates of 92.5%, 58.5% and 43.8%. The prognostic surviving factors as analysed showed that statistical differences were observed between stage I and II, I and III A (P < 0.03), N0 and N1 (P < 0.021) in 3-year survival rate, between 2-3 and 4-6 cycle chemotherapy in 1-year survival rate (P < 0.007).

Conclusion: Surgery combined with postoperative chemotherapy and radiotherapy is preferred for stages I and II, N0 and N1 lesions of SCLC.

Publication types

  • English Abstract

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carcinoma, Small Cell / drug therapy*
  • Carcinoma, Small Cell / mortality
  • Carcinoma, Small Cell / surgery
  • Chemotherapy, Adjuvant
  • Cyclophosphamide / administration & dosage
  • Doxorubicin / administration & dosage
  • Etoposide / administration & dosage
  • Female
  • Follow-Up Studies
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / mortality
  • Lung Neoplasms / surgery
  • Male
  • Methotrexate / administration & dosage
  • Middle Aged
  • Postoperative Period
  • Survival Rate
  • Vincristine / administration & dosage

Substances

  • Vincristine
  • Etoposide
  • Doxorubicin
  • Cyclophosphamide
  • Methotrexate

Supplementary concepts

  • ACE protocol 1
  • COMVP protocol